GSKGSK plc
What is the market doing?
No clear lean: nothing decisive, though in a downtrend (−10% vs 200-day).
In a downtrend, below its 50- and 200-day averages. Oversold (RSI 15). Price is −10% vs its 200-day average.
A token position, settled Sep 15, 2026, about a week of normal trading to cover. Up 8.2% since the previous count, up from 0.2% of shares outstanding three months ago.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How GSK is trading
GSK plc is +17% over the past year while the S&P 500 is +18%: 0.95 points behind the market.
1-year return · S&P 500 +18%
- vs 200-day average
- −10%
vs 200-day average · a clear downtrend
- RSI (14)
- 15
RSI (14) · oversold, sold harder than it has been bought
- Below its 52-week high
- 23%
Below its 52-week high
Details›
- Last close2026-10-09
- $46.51
- 1 monthS&P 500 +2.7%
- −3.4%
- 1 yearS&P 500 +18%
- +17%
- 5 yearsS&P 500 +88%
- +43%
- vs 50-day average$50.12
- −7.2%
- 52-week high
- $60.14
- 52-week low
- $38.51
- Annualised volatility
- 27%
| Year | Return |
|---|---|
| 2026 (year to date) | −3.5% |
| 2025 | +51% |
| 2024 | −5.1% |
| 2023 | +9.7% |
| 2022 | −17% |
| 2021 | +27% |
| 2020 | −18% |
| 2019 | +29% |
| 2018 | +14% |
| 2017 | −3.0% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 9 of 10 | +2.9% |
| Feb | 10 | 5 of 10 | +1.3% |
| Mar | 10 | 8 of 10 | +1.9% |
| Apr | 10 | 6 of 10 | +1.3% |
| May | 10 | 6 of 10 | +1.5% |
| Jun | 10 | 4 of 10 | −1.2% |
| Jul | 11 | 6 of 11 | +0.14% |
| Aug | 11 | 5 of 11 | −0.53% |
| Sep | 11 | 4 of 11 | −1.6% |
| Oct | 11 | 4 of 11 | −0.65% |
| Nov | 10 | 6 of 10 | +1.6% |
| Dec | 10 | 8 of 10 | +1.1% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Drug Manufacturers, General
Ranks #3 of 7 by RyuScore